What were GE HealthCare's Q1 2026 results?

Revenue came in at the high end of expectations, but specific profit or EPS figures were not disclosed.

What was the impact of the recall on GE HealthCare's results?

The recall affected Q1 results and led to a reduction in full-year profit and cash flow guidance.

Did GE HealthCare disclose specific revenue or profit figures?

No, it only stated that revenue was at the high end of expectations without providing numbers.

GE HealthCare Q1 Revenue Beats Expectations, Guidance Cut

Q: Why did GE HealthCare cut its 2026 guidance?

Due to higher input costs and a supplier-related recall in the Pharma segment.

GE HealthCare Technologies reported first-quarter 2026 revenue at the high end of expectations, but reduced full-year profit and cash flow guidance to reflect higher input costs and a supplier-related recall in the Pharma segment.

GE HealthCare Technologies (NASDAQ:GEHC) announced first-quarter 2026 results that management said landed at the high end of expectations on revenue. However, full-year profit and cash flow guidance were reduced to reflect higher input costs and a first-quarter supplier-related recall in Pharma.

Key Financial Results

Metric	Q1 2026
Revenue	High end of expectations
Net Income	Not disclosed
EPS	Not disclosed
Free Cash Flow	Not disclosed

Note: The company did not provide specific figures, only stating that revenue was at the high end of expectations.

Highlights from the Statement

Management attributed the guidance cut to two main factors:

Higher input costs during the quarter.
A supplier-related recall in the Pharma segment that impacted results.

Future Guidance

The company lowered its guidance for both profit and cash flow for the full year 2026, without providing specific numbers. The impact of higher costs and the recall is expected to persist.

Stock Impact

No stock reaction was mentioned in the announcement. Investors are likely to focus on the details of the guidance reduction and the recall's impact.

What This Means for Investors

The results show strong operational performance in revenue, but cost and supply chain challenges remain a concern. Investors should monitor the recall's development and its effect on profit margins.